Literature DB >> 27259537

Somatic mutations in histiocytic sarcoma identified by next generation sequencing.

Qingqing Liu1,2, Keith Tomaszewicz1, Lloyd Hutchinson1, Jason L Hornick3, Bruce Woda1, Hongbo Yu4,5.   

Abstract

Histiocytic sarcoma is a rare malignant neoplasm of presumed hematopoietic origin showing morphologic and immunophenotypic evidence of histiocytic differentiation. Somatic mutation importance in the pathogenesis or disease progression of histiocytic sarcoma was largely unknown. To identify somatic mutations in histiocytic sarcoma, we studied 5 histiocytic sarcomas [3 female and 2 male patients; mean age 54.8 (20-72), anatomic sites include lymph node, uterus, and pleura] and matched normal tissues from each patient as germ line controls. Somatic mutations in 50 "Hotspot" oncogenes and tumor suppressor genes were examined using next generation sequencing. Three (out of five) histiocytic sarcoma cases carried somatic mutations in BRAF. Among them, G464V [variant frequency (VF) of 43.6 %] and G466R (VF of 29.6 %) located at the P loop potentially interfere with the hydrophobic interaction between P and activating loops and ultimately activation of BRAF. Also detected was BRAF somatic mutation N581S (VF of 7.4 %), which was located at the catalytic loop of BRAF kinase domain: its role in modifying kinase activity was unclear. A similar mutational analysis was also performed on nine acute monocytic/monoblastic leukemia cases, which did not identify any BRAF somatic mutations. Our study detected several BRAF mutations in histiocytic sarcomas, which may be important in understanding the tumorigenesis of this rare neoplasm and providing mechanisms for potential therapeutical opportunities.

Entities:  

Keywords:  BRAF proto-oncogene; Histiocytic sarcoma; Next generation sequencing; Somatic mutations

Mesh:

Substances:

Year:  2016        PMID: 27259537     DOI: 10.1007/s00428-016-1965-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  33 in total

1.  dbSNP: the NCBI database of genetic variation.

Authors:  S T Sherry; M H Ward; M Kholodov; J Baker; L Phan; E M Smigielski; K Sirotkin
Journal:  Nucleic Acids Res       Date:  2001-01-01       Impact factor: 16.971

2.  Kinase-impaired BRAF mutations in lung cancer confer sensitivity to dasatinib.

Authors:  Banibrata Sen; Shaohua Peng; Ximing Tang; Heidi S Erickson; Hector Galindo; Tuhina Mazumdar; David J Stewart; Ignacio Wistuba; Faye M Johnson
Journal:  Sci Transl Med       Date:  2012-05-30       Impact factor: 17.956

3.  Successful treatment of histiocytic sarcoma with induction chemotherapy consisting of dose-escalated CHOP plus etoposide and upfront consolidation auto-transplantation.

Authors:  Hideki Tsujimura; Toshiko Miyaki; Shuhei Yamada; Takeaki Sugawara; Mikiko Ise; Shintaro Iwata; Tsukasa Yonemoto; Dai Ikebe; Makiko Itami; Kyoya Kumagai
Journal:  Int J Hematol       Date:  2014-07-26       Impact factor: 2.490

4.  Malignant histiocytic neoplasms of the small intestine.

Authors:  S Milchgrub; O W Kamel; E Wiley; F Vuitch; M L Cleary; R A Warnke
Journal:  Am J Surg Pathol       Date:  1992-01       Impact factor: 6.394

5.  Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy.

Authors:  Jessica L Heath; Shelly E Burgett; Ana M Gaca; Ronald Jaffe; Daniel S Wechsler
Journal:  Pediatr Blood Cancer       Date:  2014-05-29       Impact factor: 3.167

6.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

Review 7.  Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.

Authors:  Stephen J Boyer
Journal:  Curr Top Med Chem       Date:  2002-09       Impact factor: 3.295

8.  Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.

Authors:  Muneer H Abidi; Isaacson Tove; Rami B Ibrahim; Dan Maria; Edward Peres
Journal:  Am J Hematol       Date:  2007-10       Impact factor: 10.047

9.  Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.

Authors:  R E Board; G Ellison; M C M Orr; K R Kemsley; G McWalter; L Y Blockley; S P Dearden; C Morris; M Ranson; M V Cantarini; C Dive; A Hughes
Journal:  Br J Cancer       Date:  2009-10-27       Impact factor: 7.640

10.  Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

Authors:  Gavin M Wright; Hongdo Do; Jonathan Weiss; Naveed Z Alam; Vivek Rathi; Marzena Walkiewicz; Thomas John; Prudence A Russell; Alexander Dobrovic
Journal:  Oncotarget       Date:  2014-04-30
View more
  17 in total

1.  Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.

Authors:  Sunetra Das; Rupa Idate; Kathryn E Cronise; Daniel L Gustafson; Dawn L Duval
Journal:  Mol Cancer Ther       Date:  2019-06-07       Impact factor: 6.261

2.  Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Authors:  Sophie Voruz; Anne Cairoli; Olaia Naveiras; Laurence de Leval; Edoardo Missiaglia; Krisztian Homicsko; Olivier Michielin; Sabine Blum
Journal:  Haematologica       Date:  2017-11-02       Impact factor: 9.941

3.  Expression of enhancer of zeste homolog 2 (EZH2) protein in histiocytic and dendritic cell neoplasms with evidence for p-ERK1/2-related, but not MYC- or p-STAT3-related cell signaling.

Authors:  Xuejun Tian; Jie Xu; Christopher Fletcher; Jason L Hornick; David M Dorfman
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

Review 4.  Subsequent development of histiocytic sarcoma and follicular lymphoma: cytogenetics and next-generation sequencing analyses provide evidence for transdifferentiation of early common lymphoid precursor-a case report and review of literature.

Authors:  Sarah Péricart; Charlotte Waysse; Aurore Siegfried; Stephanie Struski; Eric Delabesse; Camille Laurent; Solène Evrard
Journal:  Virchows Arch       Date:  2019-12-05       Impact factor: 4.064

5.  Survival Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Retrospective Single-institutional Experience.

Authors:  Hiroshi Yaegashi; Takahiro Nohara; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Tomoyuki Makino; Kaname Yamashita; Koushiro Ohtsubo; Hiroko Ikeda; Atsushi Mizokami
Journal:  Cancer Diagn Progn       Date:  2022-05-03

6.  Primary splenic histiocytic sarcoma successfully treated with splenectomy: a case report and literature review.

Authors:  Masayuki Kobayashi; Keita Sugawara; Ken Suzaki; Nobuharu Kosugi
Journal:  Int Cancer Conf J       Date:  2022-04-16

Review 7.  Canine sarcomas as a surrogate for the human disease.

Authors:  Daniel L Gustafson; Dawn L Duval; Daniel P Regan; Douglas H Thamm
Journal:  Pharmacol Ther       Date:  2018-03-09       Impact factor: 12.310

8.  A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.

Authors:  Tadashi Kumamoto; Yuki Aoki; Tomoko Sonoda; Miho Yamanishi; Ayumu Arakawa; Masanaka Sugiyama; Nami Shirakawa; Sae Ishimaru; Yoshimasa Saito; Akiko Maeshima; Miho Maeda; Chitose Ogawa
Journal:  Int J Hematol       Date:  2018-10-25       Impact factor: 2.490

9.  Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status.

Authors:  Xiaoqin Zhu; Sarah Jamshed; Jian Zou; Azniv Azar; Xiuling Meng; Venu Bathini; Karen Dresser; Cara Strock; Bhargavi Yalamarti; Michelle Yang; Keith Tomaszewicz; George Tjionas; Mark C Mochel; Lloyd Hutchinson; Jacob R Bledsoe
Journal:  Mod Pathol       Date:  2021-01-22       Impact factor: 8.209

10.  Prognostic factors for histiocytic and dendritic cell neoplasms.

Authors:  Joji Shimono; Hiroaki Miyoshi; Fumiko Arakawa; Kensaku Sato; Takuya Furuta; Reiji Muto; Eriko Yanagida; Yuya Sasaki; Daisuke Kurita; Keisuke Kawamoto; Koji Nagafuji; Koichi Ohshima
Journal:  Oncotarget       Date:  2017-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.